🇺🇸 FDA
Pipeline program

DA-302168S

2024-CP-DA168-06

Phase 2 small_molecule active

Quick answer

DA-302168S for Overweight and Obesity is a Phase 2 program (small_molecule) at Chendu DIAO Pharmaceutical Group CO., LTD. with 1 ClinicalTrials.gov record(s).

Program details

Company
Chendu DIAO Pharmaceutical Group CO., LTD.
Indication
Overweight and Obesity
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials